Singh K. The effect of benfothiamine on the expression of gene SLC19A3, clinical and metabolic impairment in patients with type 2 diabetes with diabetic polyneuropathy in its various stages.

Therefore, in-depth study of the frequency and the risk factors for the development of DPN in patients with type 2 DM, development of new diagnostic tool for precise, quick and easy assessment of patients with DPN is a promising area, and the use of novel drugs, addressing the pathogenetic mechanisms involved in the progression of DPN is of great practical importance. In the dissertation work on the basis of the complex analysis of results of clinical, instrumental, biochemical methods of research, scoring techniques, gene expression analysis a theoretical generalization is presented and a new approach and understanding, for solving one of the actual tasks of modern endocrinology is presented – establishment of pathogenetic linkage between various risk factors involved in the progression of DPN in patients with type 2 DM. Based on the obtained results and analysis, a new solution of the scientific and practical task of optimization, prevention of complications, early detection and diagnosis of DPN, increased effectiveness in treatment of DPN in patients taking into account the established pathogenetic factors has been proposed. We studied the efficacy of benfothiamine in DPN treating in type 2 diabetes patients, its effect on the expression of SLC19A3 gene, clinical and metabolic disorders in patients. Detailed analysis was done to find the correlation of risk factors of DPN (glycemic levels, duration of disease and age) with small and large fiber dysfunction in various stage of DPN. It was found that large fiber dysfunction correlates to the risk factors of DPN and that age, duration of disease are major risk factors. The practical feasibility for the use of the DNS symptom score as a precise and accurate test for evaluating DPN in type 2 diabetes patients and its accuracy in correlation to major risk factors of DPN was established. The variation in the expression of THTR-2and its adaptive regulatory response in patients with type 2 DM was established. The therapeutic advantages in the use of benfothiamne as an effective novel agent which addresses the pathogenetic mechanisms of microvascular complications, and its role in the activation of the pentose phosphate shunt by altering the expression of SLC19A3 in patients with type 2 DM and DPN was established.